Family-Based Therapy Shows Superior Weight Gain in Children With ARFID, Landmark Trial Finds

The first adequately powered randomized clinical trial evaluating treatments for avoidant/restrictive food intake disorder (ARFID) has demonstrated that 2 outpatient behavioral therapies can improve symptoms in children, with family-based treatment (FBT) showing superior outcomes for weight restoration. The findings, published in the Journal of the American Academy of Child & Adolescent Psychiatry, provide the first high-quality evidence to guide treatment for a disorder that affects an estimated 2% to 6% of children and adolescents.^1,2

Unlike anorexia nervosa or bulimia nervosa, ARFID is not driven by concerns about body weight or shape. Instead, children may severely restrict food intake because of sensory sensitivities, a lack of interest in eating, or fears related to choking, vomiting, or other adverse consequences of eating.¹ Left untreated, the disorder can lead to poor growth, nutritional deficiencies, delayed development, and significant psychosocial impairment.²

“This is the first study, worldwide, to take a systematic, randomized, adequately powered approach to testing treatments for this disorder,” said lead author James Lock, MD, PhD, professor of psychiatry and behavioral sciences at Stanford Medicine, in a news release. “We now have an evidence base for how to help children with ARFID, at the age when they often present for treatment.”³

Family-Based Treatment Promotes Greater Weight Recovery

The multicenter trial enrolled 98 children aged 6 to 12 years who met diagnostic criteria for ARFID and were underweight. Participants were randomly assigned to receive either FBT-ARFID or psychoeducational motivational therapy (PMT), with both interventions consisting of 14 telehealth sessions delivered over approximately 4 months.¹

FBT empowers parents to take an active role in helping their child overcome restrictive eating behaviors while therapists provide guidance throughout the process. In contrast, PMT emphasizes helping children understand their condition, identify personal motivations for dietary change, and reduce family conflict surrounding meals, while placing behavioral change largely in the child's hands.^1,3

At the conclusion of treatment, children receiving FBT experienced significantly greater improvements in percent expected body weight compared with those receiving PMT (Cohen's d = 0.77; P < .0001). Investigators also found that children with more severe ARFID symptoms at baseline experienced greater symptom improvement with FBT than PMT, suggesting family involvement may be particularly beneficial in more complex cases.¹

Importantly, both treatment approaches significantly reduced overall ARFID symptom severity, indicating that each may have a role depending on an individual child's clinical presentation.¹

“We now have two treatments that work for children aged 6 to 12 with ARFID,” study coauthor Brittany Matheson, PhD, said in the Stanford Medicine release. “Family-based treatment seems to help kids gain weight more quickly, but both family and individual treatment can be helpful. We are so excited to have two treatments that work when we had zero before.”³

Distinguishing ARFID From Typical Picky Eating

Although selective eating is common during early childhood, ARFID represents the severe end of the spectrum and extends well beyond typical picky eating. Patients often avoid entire food groups, consume fewer than 10 preferred foods, or experience significant anxiety surrounding meals. These behaviors can result in nutritional deficiencies, dependence on nutritional supplements, impaired growth, and avoidance of social situations involving food.²

The diagnosis, added to the Diagnostic and Statistical Manual of Mental Disorders in 2013, frequently coexists with conditions such as autism spectrum disorder, anxiety disorders, and attention-deficit/hyperactivity disorder, further emphasizing the need for individualized, multidisciplinary care.^1,2

Implications for Pharmacists

Pharmacists practicing in pediatric, ambulatory care, and nutrition support settings can play an important role in identifying children at risk for ARFID. Patients presenting with persistent nutritional deficiencies, failure to thrive, vitamin supplementation needs, or prolonged restrictive eating behaviors may warrant referral for further evaluation.²

In addition to monitoring medication- and nutrition-related concerns, pharmacists can help educate families that ARFID is a recognized psychiatric disorder rather than simply "picky eating." Early recognition and timely referral to multidisciplinary treatment teams may improve nutritional recovery and long-term developmental outcomes, particularly as evidence-based interventions become more widely available.^1-3

REFERENCES

1. Lock J, Matheson B, Jo B, et al. Family vs Individual Treatment for Children With Avoidant/Restrictive Food Intake Disorder: A Randomized Clinical Trial. J Am Acad Child Adolesc Psychiatry. Published online April 20, 2026. doi:10.1016/j.jaac.2026.04.007

2. Ellison C, Philpot U, Fuller S, et al. What is avoidant restrictive food intake disorder?. Br J Gen Pract. 2024;74(745):362-363. Published 2024 Jul 25. doi:10.3399/bjgp24X738957

3. Stanford Medicine. Two treatments help ARFID, a common pediatric eating disorder, Stanford Medicine trial shows. EurekAlert! Published June 29, 2026. Accessed June 30, 2026. https://www.eurekalert.org/news-releases/1133918